Detalhe da pesquisa
1.
TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry.
Cell
; 186(16): 3427-3442.e22, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37421949
2.
Acute Treatment With XMetA Activates Hepatic Insulin Receptors and Lowers Blood Glucose in Normal Mice.
J Cell Biochem
; 116(9): 2109-19, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25808283
3.
Differential pathway coupling of the activated insulin receptor drives signaling selectivity by XMetA, an allosteric partial agonist antibody.
J Pharmacol Exp Ther
; 353(1): 35-43, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25613982
4.
Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1ß antibody with differential receptor-modulating properties.
J Pharmacol Exp Ther
; 348(1): 202-15, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24194526
5.
Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity.
J Biol Chem
; 285(27): 20607-14, 2010 Jul 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-20410301
6.
XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1ß-mediated diseases.
MAbs
; 3(1): 49-60, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21048425
7.
Development of XPA067.06, a potent high affinity human anti-gastrin monoclonal antibody.
Biochem Pharmacol
; 76(3): 340-52, 2008 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18589401
8.
Kinetic analysis of a high-affinity antibody/antigen interaction performed by multiple Biacore users.
Anal Biochem
; 352(2): 208-21, 2006 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16564019